By Richard Manning and Fred Selck
A new class of anti-obesity medications (AOMs) called GLP-1s have been shown to be highly effective at helping people lose weight. Given the efficacy of GLP-1s, and the significant long-term costs associated with treating obesity and its related diseases, there is increasing pressure on public and private health insurers to cover AOMs. This white paper by Richard Manning and Fred Selck finds that when current state market dynamics and assumptions are included in precise financial analytics, treating obesity does not present the threat to Medicare’s financial solvency that other recently published analyses suggest.